Scientific publications

Identification of mutations associated with acquired resistance to sunitinib in renal cell-cancer

Mar 8, 2019 | Magazine: International Journal of Cancer

Elgendy M (1,2), Fusco JP (3,4), Segura V (5), Lozano MD (4,6,7), Minucci S (1,8), Echeveste JI (4,6), Gurpide A (3,4), Andueza M (3,4), Melero I (4,7,9), Sanmamed MF (3,4), Ruiz MR (3,4), Calvo A (4,10), Pascual JI (4,11), Velis JM (4,11), Miñana B (4,11), Valle RD (4,12), Pio R (4,7,13), Agorreta J (4,7,13), Abengozar M (4,6), Colecchia M (14), Brich S (14), Renne SL (14), Guruceaga E (5), Patiño-García A (4,13,15), Perez-Gracia JL (3,4,7).


Sunitinib is one of the most widely used targeted therapeutics for renal cell-cancer (RCC) but acquired resistance against targeted therapies remains a major clinical challenge.

To dissect mechanisms of acquired resistance and unravel reliable predictive biomarkers for sunitinib in renal cell-cancer (RCC), we sequenced the exons of 409 tumor-suppressor genes and oncogenes in paired tumor samples from an RCC patient, obtained at baseline and following development of acquired resistance to sunitinib.

From newly arising mutations, we selected, using in-silico prediction models, 6 predicted to be deleterious, located in G6PD, LRP1B, SETD2, TET2, SYNE1 and DCC.

Consistently, immunoblotting analysis of lysates derived from sunitinib-desensitized RCC cells and their parental counterparts showed marked differences in the levels and expression pattern of the proteins encoded by these genes.

Our further analysis demonstrates essential roles for these proteins in mediating sunitinib cytotoxicity and shows that their loss of function render tumor cells resistant to sunitinib in vitro and in vivo.

Finally, sunitinib resistance induced by continuous exposure or by inhibition of the 6 proteins was overcome by treatment with cabozantinib or a low-dose combination of lenvatinib and everolimus.

Collectively, our results unravel novel markers of acquired resistance to sunitinib and clinically relevant approaches for overcoming this resistance in RCC.

CITATION  Int J Cancer. 2019 Oct 1;145(7):1991-2001.
doi: 10.1002/ijc.32256. Epub 2019 Mar 30